PMID- 33847633
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 15
DP  - 2021 Apr 16
TI  - Effects of continuous use of metformin on cardiovascular outcomes in patients 
      with type 2 diabetes after acute myocardial infarction: A protocol for systematic 
      review and meta-analysis.
PG  - e25353
LID - 10.1097/MD.0000000000025353 [doi]
LID - e25353
AB  - BACKGROUND: To our knowledge, no meta-analyses or reviews have investigated the 
      efficacy and safety of metformin on cardiovascular outcomes after acute 
      myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). We 
      thus conduct a high-quality systematic review and meta-analysis to assess the 
      efficacy and safety of metformin on cardiovascular outcomes after AMI in patients 
      with T2DM. METHODS: In this systematic review and meta-analysis, we will search 
      PUBMED, Scopus, EMBASE, and Cochrane Library databases through April, 2021. The 
      study is structured to adhere to PRISMA guidelines (i.e., Preferred Reporting 
      Items for Systematic Reviews and Meta-analyses). The literature search, data 
      extraction, and quality assessments are conducted independently by 2 authors. 
      Outcome measures include all-cause mortality; complications such as acute kidney 
      injury, lactic acidosis, hospitalization for AMI or stroke, or death. Where 
      disagreement in the collection of data occurs, this is resolved through 
      discussion. Review Manager Software (v 5.3; Cochrane Collaboration) is used for 
      the meta-analysis. Two independent reviewers will assess the risk of bias of the 
      included studies at study level. RESULTS: It is hypothesized that metformin use 
      at the post-AMI is associated with decreased risk of cardiovascular disease and 
      death in patients with T2DM. CONCLUSIONS: This study expects to provide credible 
      and scientific evidence for the efficacy and safety of metformin on 
      cardiovascular outcomes after AMI in patients with T2DM. REGISTRATION NUMBER: 
      10.17605/OSF.IO/S3MBP.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Shen, Chuanwen
AU  - Shen C
AD  - Department of Emergency, Qianjiang Central Hospital of Chongqing, Chongqing, 
      China.
FAU - Tan, Shuying
AU  - Tan S
FAU - Yang, Jun
AU  - Yang J
LA  - eng
GR  - 2019016/Chongqing qianjiang district science and technology bureau project/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Cardiovascular Diseases/epidemiology
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/*drug therapy/*epidemiology
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Metformin/administration & dosage/*therapeutic use
MH  - Myocardial Infarction/*epidemiology/mortality
MH  - Research Design
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC8051987
COIS- The authors report no conflicts of interest.
EDAT- 2021/04/14 06:00
MHDA- 2021/04/29 06:00
PMCR- 2021/04/16
CRDT- 2021/04/13 12:12
PHST- 2021/03/09 00:00 [received]
PHST- 2021/03/11 00:00 [accepted]
PHST- 2021/04/13 12:12 [entrez]
PHST- 2021/04/14 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
PHST- 2021/04/16 00:00 [pmc-release]
AID - 00005792-202104160-00029 [pii]
AID - MD-D-21-01844 [pii]
AID - 10.1097/MD.0000000000025353 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Apr 16;100(15):e25353. doi: 
      10.1097/MD.0000000000025353.